QQQ   349.61 (+0.35%)
AAPL   177.19 (+1.00%)
MSFT   331.36 (-0.46%)
META   262.84 (+0.31%)
GOOGL   122.98 (-1.31%)
AMZN   121.29 (+0.98%)
TSLA   199.12 (+3.08%)
NVDA   403.25 (+3.54%)
NIO   7.39 (-4.03%)
BABA   78.31 (-3.29%)
AMD   125.94 (-0.86%)
T   15.60 (+0.65%)
F   12.61 (+4.30%)
MU   72.13 (-2.43%)
CGC   0.87 (-1.14%)
GE   102.13 (-0.59%)
DIS   87.10 (-1.35%)
AMC   4.60 (-0.86%)
PFE   37.09 (-1.36%)
PYPL   61.51 (+2.14%)
NFLX   391.10 (+3.23%)
QQQ   349.61 (+0.35%)
AAPL   177.19 (+1.00%)
MSFT   331.36 (-0.46%)
META   262.84 (+0.31%)
GOOGL   122.98 (-1.31%)
AMZN   121.29 (+0.98%)
TSLA   199.12 (+3.08%)
NVDA   403.25 (+3.54%)
NIO   7.39 (-4.03%)
BABA   78.31 (-3.29%)
AMD   125.94 (-0.86%)
T   15.60 (+0.65%)
F   12.61 (+4.30%)
MU   72.13 (-2.43%)
CGC   0.87 (-1.14%)
GE   102.13 (-0.59%)
DIS   87.10 (-1.35%)
AMC   4.60 (-0.86%)
PFE   37.09 (-1.36%)
PYPL   61.51 (+2.14%)
NFLX   391.10 (+3.23%)
QQQ   349.61 (+0.35%)
AAPL   177.19 (+1.00%)
MSFT   331.36 (-0.46%)
META   262.84 (+0.31%)
GOOGL   122.98 (-1.31%)
AMZN   121.29 (+0.98%)
TSLA   199.12 (+3.08%)
NVDA   403.25 (+3.54%)
NIO   7.39 (-4.03%)
BABA   78.31 (-3.29%)
AMD   125.94 (-0.86%)
T   15.60 (+0.65%)
F   12.61 (+4.30%)
MU   72.13 (-2.43%)
CGC   0.87 (-1.14%)
GE   102.13 (-0.59%)
DIS   87.10 (-1.35%)
AMC   4.60 (-0.86%)
PFE   37.09 (-1.36%)
PYPL   61.51 (+2.14%)
NFLX   391.10 (+3.23%)
QQQ   349.61 (+0.35%)
AAPL   177.19 (+1.00%)
MSFT   331.36 (-0.46%)
META   262.84 (+0.31%)
GOOGL   122.98 (-1.31%)
AMZN   121.29 (+0.98%)
TSLA   199.12 (+3.08%)
NVDA   403.25 (+3.54%)
NIO   7.39 (-4.03%)
BABA   78.31 (-3.29%)
AMD   125.94 (-0.86%)
T   15.60 (+0.65%)
F   12.61 (+4.30%)
MU   72.13 (-2.43%)
CGC   0.87 (-1.14%)
GE   102.13 (-0.59%)
DIS   87.10 (-1.35%)
AMC   4.60 (-0.86%)
PFE   37.09 (-1.36%)
PYPL   61.51 (+2.14%)
NFLX   391.10 (+3.23%)
NASDAQ:MEDP

Medpace (MEDP) Stock Forecast, Price & News

$207.08
+3.53 (+1.73%)
(As of 01:51 PM ET)
Compare
Today's Range
$204.16
$208.57
50-Day Range
$178.78
$210.88
52-Week Range
$130.79
$241.48
Volume
125,107 shs
Average Volume
331,131 shs
Market Capitalization
$6.32 billion
P/E Ratio
26.21
Dividend Yield
N/A
Price Target
$241.00

Medpace MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
16.5% Upside
$241.00 Price Target
Short Interest
Bearish
8.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
1.49mentions of Medpace in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$7.02 M Sold Last Quarter
Proj. Earnings Growth
13.32%
From $8.11 to $9.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

241st out of 1,009 stocks

Commercial Physical Research Industry

8th out of 16 stocks


MEDP stock logo

About Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Stock News Headlines

Medpace (NASDAQ:MEDP) Upgraded to Buy by StockNews.com
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Medpace Holdings Crushed Analyst Expectations
Medpace (NASDAQ:MEDP) Stock Price Down 6.3% on Insider Selling
Medpace (NASDAQ:MEDP) Rating Increased to Buy at StockNews.com
Q1 2023 Medpace Holdings Inc Earnings Call
Medpace Q1 2023 Earnings Preview
Here's what Wall Street expects from Medpace's earnings
Medpace (MEDP) Scheduled to Post Quarterly Earnings on Monday
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

MEDP Company Calendar

Last Earnings
4/24/2023
Today
5/30/2023
Next Earnings (Estimated)
7/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEDP
Employees
5,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$241.00
High Stock Price Forecast
$252.00
Low Stock Price Forecast
$233.00
Forecasted Upside/Downside
+18.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$245.37 million
Pretax Margin
19.42%

Debt

Sales & Book Value

Annual Sales
$1.56 billion
Cash Flow
$8.59 per share
Book Value
$12.42 per share

Miscellaneous

Free Float
22,661,000
Market Cap
$6.21 billion
Optionable
Optionable
Beta
1.42

Key Executives

  • August James TroendleAugust James Troendle
    Chairman & Chief Executive Officer
  • Jesse J. GeigerJesse J. Geiger
    President
  • Susan E. Burwig
    Executive Vice President-Operations
  • Kevin M. BradyKevin M. Brady
    Chief Financial Officer & Treasurer
  • Brandon Ebken
    Chief Information Officer













MEDP Stock - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price forecast for 2023?

3 analysts have issued 12 month price targets for Medpace's shares. Their MEDP share price forecasts range from $233.00 to $252.00. On average, they expect the company's stock price to reach $241.00 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How have MEDP shares performed in 2023?

Medpace's stock was trading at $212.41 at the beginning of 2023. Since then, MEDP stock has decreased by 4.2% and is now trading at $203.55.
View the best growth stocks for 2023 here
.

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 24th 2023.
View our MEDP earnings forecast
.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) released its earnings results on Monday, April, 24th. The company reported $2.27 EPS for the quarter, beating analysts' consensus estimates of $1.76 by $0.51. The business earned $434.07 million during the quarter, compared to the consensus estimate of $402.83 million. Medpace had a trailing twelve-month return on equity of 75.20% and a net margin of 16.44%. The firm's revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.69 EPS.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $7.81-$8.40 for the period, compared to the consensus earnings per share estimate of $7.76. The company issued revenue guidance of $1.75 billion-$1.80 billion, compared to the consensus revenue estimate of $1.71 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.43%), Wasatch Advisors LP (6.09%), State Street Corp (2.76%), Geode Capital Management LLC (1.93%), Boston Trust Walden Corp (1.83%) and Dimensional Fund Advisors LP (1.77%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends
.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $203.55.

How much money does Medpace make?

Medpace (NASDAQ:MEDP) has a market capitalization of $6.21 billion and generates $1.56 billion in revenue each year. The company earns $245.37 million in net income (profit) each year or $7.90 on an earnings per share basis.

How many employees does Medpace have?

The company employs 5,200 workers across the globe.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444.

This page (NASDAQ:MEDP) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -